PDCD1 and melanoma: Since this kinase positively correlated with PPARγ activity, and as its genetic and pharmacologic inhibition together with PD1-blocking Ab improved metabolic fitness and anti-tumor activity of T-cells against murine melanoma, PPARγ antagonists may be envisioned as agents to improve tumor control.